Piramal Pharma Q1 Results FY27: Date, Revenue Estimates, Key Catalysts and Share Price Target

July 3, 2026
Posted by: Kunal Singla
Category: News

Piramal Pharma CMP Rs.168. Q1 FY27E revenue Rs.1,854-2,133 Cr. PAT estimate Rs.-36–46 Cr. 12-month target Rs.160-182.

Piramal Pharma Q1 Results FY27 is coming into focus as investors position ahead of the July-August 2026 results season, with Piramal Pharma shares trading at Rs.168 against a market capitalisation of Rs.22,393 Cr and a price-to-earnings multiple of Not meaningful. As a pharmaceuticals and life sciences name on the NSE and BSE, Piramal Pharma enters the Piramal Pharma Q1 Results FY27 print with the Street watching revenue momentum, margin trajectory and management commentary on FY27 guidance.

This Piramal Pharma Q1 Results FY27 preview is built on a trailing-growth framework applied to the company’s Q1 FY26 base of Rs.1,992 Cr revenue and Rs.-82 Cr net profit, using the most recent year-on-year growth signal from Q4 FY26. This Q1 prediction is a Uniresearch trailing-growth projection, not a formal analyst estimate, and should be read alongside the company’s own guidance once released.

Get Free Investment Predictions and Piramal Pharma Research at Univest

Table of Contents

About Piramal Pharma

Piramal Pharma (NSE: PPLPHARMA) operates in the pharmaceuticals and life sciences space and is tracked on Univest under its NSE and BSE listings. Ahead of the Piramal Pharma Q1 Results FY27 print, the company’s Q4 FY26 base shows revenue of Rs.2,798 Cr and net profit of Rs.-9 Cr, forming the base against which the Piramal Pharma Q1 Results FY27 estimates in this article are built. This Piramal Pharma Q1 Results FY27 snapshot is intended as a starting point for research, not a substitute for the company’s own disclosures.

Piramal Pharma Q1 FY27 Estimates

Metric	Q1 FY27E (Range)	Q1 FY26 Actual	YoY Growth
Revenue (Rs. Cr)	1,854-2,133	1,992	+0.1%
Net Profit / PAT (Rs. Cr)	-36–46	-82	-50.0%
Results Date	July-August 2026 (indicative)
12-Month Target (Uniresearch Estimate)	Rs.160-182

Univest, a SEBI-Registered Investment Advisor, Tracks Piramal Pharma Ahead of Q1 FY27 Results

Key Catalysts to Watch

1. CDMO Pipeline Visibility

Steady traction in the CDMO and contract manufacturing pipeline supporting revenue visibility is one of the primary variables that analysts are tracking ahead of Piramal Pharma’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Piramal Pharma share price target or faces renewed pressure.

2. New Product Approvals

New product approvals and launches adding to the domestic and export portfolio is one of the primary variables that analysts are tracking ahead of Piramal Pharma’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Piramal Pharma share price target or faces renewed pressure.

3. Capacity Scale-Up

Operating leverage from scale-up in recently commissioned manufacturing capacity is one of the primary variables that analysts are tracking ahead of Piramal Pharma’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Piramal Pharma share price target or faces renewed pressure.

Download the Univest iOS App or Univest Android App to track Piramal Pharma’s live price and Q1 FY27 result updates.

Key Risks to the Piramal Pharma Q1 Results FY27 Outlook

Pricing pressure in key export markets, particularly the US generics segment.
Regulatory or plant compliance issues affecting supply continuity.
R&D and capacity expansion costs weighing on near-term profitability.

Q4 FY26 Performance Context for the Piramal Pharma Q1 Results FY27 Print

Piramal Pharma closed Q4 FY26 with revenue of Rs.2,798 Cr and net profit of Rs.-9 Cr, a year-on-year revenue change of +0.1% and PAT change of -105.8%. This base underpins the Piramal Pharma Q1 Results FY27 projection used in this preview and should be read alongside the company’s own Piramal Pharma Q1 Results FY27 commentary once reported.

Technical Analysis Ahead of Piramal Pharma Q1 Results FY27

Piramal Pharma shares last traded at Rs.168. For the current 52-week high and low, support and resistance levels, investors should check the live chart on the Univest app or the NSE website, since these levels move intraday and are not reproduced here to avoid stale data.

Share Price Target Based on the Piramal Pharma Q1 Results FY27 Outlook

3-6 Month Target

Over a 3-6 month horizon, the Piramal Pharma Q1 Results FY27 trailing-growth framework points to a range of Rs.162-175 for Piramal Pharma, contingent on the Piramal Pharma Q1 Results FY27 print matching or beating the trailing growth trend.

12-Month Target

The 12-month target (Uniresearch estimate) tied to this Piramal Pharma Q1 Results FY27 view for Piramal Pharma works out to Rs.160-182, built on the same trailing revenue growth trend and current valuation multiple. Tracking is how Univest research categorises the stock heading into Piramal Pharma Q1 Results FY27, not a formal Buy or Sell call.

FY27-28 Outlook

Looking out to FY27-28, a sustained continuation of the growth trajectory implied by this Piramal Pharma Q1 Results FY27 analysis would put Piramal Pharma in a Rs.164-194 range, though this is sensitive to sector-wide demand, cost trends and any change in the company’s competitive position.

What to Watch in the Piramal Pharma Q1 Results FY27 Print

Revenue and PAT versus the Piramal Pharma Q1 Results FY27 estimate range in this preview.
Management commentary on FY27 growth guidance and margin trajectory relevant to the Piramal Pharma Q1 Results FY27 narrative.
Steady traction in the CDMO and contract manufacturing pipeline supporting revenue visibility
Pricing pressure in key export markets, particularly the US generics segment

Conclusion on Piramal Pharma Q1 Results FY27

Piramal Pharma enters the Q1 FY27 results season trading at Rs.168, with the 12-month Uniresearch target range of Rs.160-182 reflecting a tracking stance. Investors tracking the Piramal Pharma Q1 Results FY27 print should watch the catalysts and risks above and consult a SEBI-registered advisor before making investment decisions around the results.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

FAQs on Piramal Pharma Q1 Results FY27

When are Piramal Pharma Q1 FY27 results expected?

Ans. Piramal Pharma’s Q1 FY27 results are expected in the July-August 2026 window, in line with the broader NSE and BSE results season for the quarter ending June 2026.

What is the Piramal Pharma Q1 FY27 revenue estimate?

Ans. The Uniresearch trailing-growth estimate for Piramal Pharma’s Q1 FY27 revenue is Rs.1,854-2,133 Cr, based on the Q1 FY26 base of Rs.1,992 Cr.

What is the Piramal Pharma share price target?

Ans. The 12-month Uniresearch estimate for Piramal Pharma share price target is Rs.160-182, based on trailing growth and current valuation multiples.

Is Piramal Pharma a good buy before Q1 FY27 results?

Ans. Piramal Pharma is tracking heading into Q1 FY27 results. Investors should weigh the catalysts and risks in this article and consult a SEBI-registered advisor before investing.

What should investors watch in Piramal Pharma’s Q1 FY27 results?

Ans. Key items include revenue and PAT versus estimates, management commentary on FY27 guidance, and steady traction in the CDMO and contract manufacturing pipeline supporting revenue visibility.

Where can I track Piramal Pharma share price live?

Ans. Piramal Pharma share price can be tracked live on the Univest app and website, along with research updates from SEBI-registered analysts.

News

Author: Kunal Singla

Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.